Surmodics tops Q4 sales estimates, misses on EPS

This article was originally published here

SurmodicsShares in Surmodics (NSDQ:SRDX) fell today after the medical device maker topped sales expectations but missed EPS estimates on Wall Street with its fourth-quarter financial results.

The Eden Prairie, Minn.-based company was in the red this quarter, posting a net loss of -$1.8 million, or -13¢ per share, on sales of $23 million for the three months ended Sept. 30. Sales were up 15% compared to the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Surmodics tops Q4 sales estimates, misses on EPS appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply